Comparison of dual-color dual-hapten brightfield in situ hybridization (DDISH) and fluorescence in situ hybridization in breast cancer HER2 assessment

Pathology Research and Practice

Volumn 209, Issue 3, 2013, Pages 147-150

  Kosa, Csaba ^a   Kardos, Laszlo ^b   Kovacs, Judit ^c   Szollosi, Zoltan ^c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Kenezy Korhaz Rendelointezet   (Hungary)

^c Borsod County Teaching Hospital   (Hungary)

Author keywords

Breast cancer; Chromosome 17; DDISH; FISH; HER2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ANALYTIC METHOD; ARTICLE; BREAST CARCINOMA; CELL ASSAY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DUAL COLOR DUAL HAPTEN BRIGHTFIELD IN SITU HYBRIDIZATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE IDENTIFICATION; HER2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RELIABILITY; REPRODUCIBILITY; SIGNAL DETECTION; VALIDATION STUDY;

BREAST NEOPLASMS; FEMALE; HAPTENS; HUMANS; IN SITU HYBRIDIZATION; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS;

EID: 84875379553     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2013.01.006     Document Type: Article

References (15)

1. Carbone A., Botti G., Gloghini A.A., Simone G., Truini M., Curcio M.P., Gasparini P., Mangia A., Perin T., Salvi S., Testi A., Verderio P. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists. J. Mol. Diagn. 2008, 10:528-536.
2. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.F. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor 2 testing in breast cancer. J. Clin. Oncol. 2007, 25:118-145.
3. Papouchado B.G., Myles J., Lloyd R.V., Stoler M., Oliveira A.M., Downs-Kelly E., Morey A., Bilous M., Nagle R., Prescott N., Wang L., Dragovich L., McElhinny A., Garcia C.F., Ranger-Moore J., Free H., Powell W., Loftus M., Pettay J., Gaire F., Roberts C., Dietel M., Roche P., Grogan T., Tubbs R., Myles J., Lloyd R.V., Stoler M., Oliveira A.M., Downs-Kelly E., Morey A., Bilous M., Nagle R., Prescott N., Wang L., Dragovich L., McElhinny A., Garcia C.F., Ranger-Moore J., Free H., Powell W., Loftus M., Pettay J., Gaire F., Roberts C., Dietel M., Roche P., Grogan T., Tubbs R. Silver in situ hybridization (SISH) for determination for HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am. J. Surg. Pathol. 2010, 34:767-776.
4. Vogel C.L., Cobleigh D., Tripathy D., Mass R., Murphy M., Stewart S.J. Superior outcomes with herceptin (trastuzumab) (H) in fluorescence in situ hybridization (FISH)-selected patients. Proc Am Soc Clin Oncol 2001, 20:22a.
5. Varshney D., Zhou Y.Y., Geller S.A., Alsabeh R. Determination of HER-2 status and chromosome polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am. J. Clin. Pathol. 2004, 121:70-77.
6. Nitta H., Hauss-Wegrzyniak B., Lehrkamp M., Murillo A.E., Gaire F., Farrell M., Walk E., Penault-Llorca F., Kurosumi M., Dietel M., Wang L., Loftus M., Pettay J., Tubbs R.R., Grogan T.M. Development of automated bright field double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN17) for breast carcinomas and an assay performance comparison to manual dual colour HER2 fluorescence in situ hybridization (FISH). Diagn. Pathol. 2008, 3:41.
7. Bartlett J.M., Campbell F.M., Ibrahim M., O'Grady A., Kay E., Faulkes C., Collins N., Starczynski J., Morgan J.M., Jasani B., Miller K. A UK NEQAS ISH multicenter ring study using the Ventana HER2 dual-colour ISH Assay. Am. J. Clin. Pathol. 2011, 135:157-162.
8. Bartlett J.M., Campbell F.M., Ibrahim M., Wencyk P., Ellis I., Kay E., Connolly Y., O'Grady A., Di Palma S., Starczynski J., Morgan J.M., Jasani B., Miller K. Chromogenic in situ hybridization with FISH. Am. J. Clin. Pathol. 2009, 132:514-520.
9. Dietel M., Ellis I.O., Höfler H., Kreipe H., Moch H., Dankof A., Kölbe K., Kristiansen G. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch. 2007, 451:19-25.
10. Dowsett M., Cooke T., Ellis I.O., Gullick W.J., Gusterson B., Mallon E., Walker R. Assessment of HER2 status in breast cancer: why, when and how?. Eur. J. Cancer 2000, 36:170-176.
11. Dowsett M., Hanna W.M., Kockx M., Penault-Liorca F., Gutjhar T., Habben K., van de Vijver M.J.M.J. Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod. Pathol. 2007, 20:584-591.
12. Piccart M., Lohrisch C., Di Leo A., Larismont D. The predictive value of HER2 in breast cancer. Oncology 2001, 61:73-82.
13. Mass R.D., Press M., Anderson S., Murphy M., Slamon D. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc. Am. Soc. Clin. Oncol. 2001, 20:22a.
14. Tuma R.S. Inconsistency of HER2 test raises questions. J. Natl. Cancer Inst. 2007, 99:1064-1065.
15. Koh Y.W., Lee H.J., Lee J.W., Kang J., Gong G. Dual-colour silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer. Mod. Pathol. 2011, 24:794-800.